Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug hopes to slow kidney damage in rare alport syndrome

NCT ID NCT07523581

First seen Apr 17, 2026 · Last updated May 23, 2026 · Updated 7 times

Summary

This study tests an experimental drug called exaluren in people aged 12 and older with Alport syndrome caused by specific genetic errors. The goal is to see if it can reduce kidney damage. 24 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 weeks. The study measures changes in kidney structure and protein levels in urine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME, X-LINKED are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Alder Hey Children's NHS Foundation Trust

    Liverpool, L12 2AP, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Denver Nephrologists PC, Colorado Kidney Care PC

    Denver, Colorado, 80220, United States

  • Great Ormond Street Hospital

    London, WC1N 3JH, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal Free Hospital

    London, NW3 2QG, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal Manchester Children's Hospital

    Manchester, M13 9WL, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.